BB's Stock Haven

[LoveItInBishop]

DRNK - Stock Repurchase, SS Restructuring, Acquisitions, Distribution Deals, Debt re-negotiation/elimination, New products, No RS in 2017:

(for additional information on NOHO please visit www.nohodrink.com and our full product site at www.imbutek.com and at www.instagram.com/nohodrink, as well as at www.twitter.com/nohodrink

Issuer Stock Repurchase Program
http://ih.advfn.com/p.php?pid=nmona&article=75194608&symbol=DRNK
The Company intends to activate a stock repurchase program ("Stock Repurchase") pursuant to Rule 10b-18 which allows Issuers to post bids for and purchases of an issuer's common stock by or for an issuer or an "affiliated purchaser" of an issuer. The safe harbor excludes bids and purchases made during certain corporate events such as mergers, tender offers, and distributions that involve the issuer. The safe harbor provides only that certain, specific provisions of the securities laws will not be considered to have been violated solely by reason of the manner, timing, price, or volume of such repurchases, provided the repurchases are made within the limitations of the Rule. The company will disclose all information regarding the common stock the Company has repurchased as it is important and useful to investors to include specific information regarding repurchase activity by issuers and their affiliates.

Cancellation of Class B Preferred Shares
http://ih.advfn.com/p.php?pid=nmona&article=75194608&symbol=DRNK
NOHO has instructed counsel to cancel all Class B preferred shares. As a result, the insiders will no longer have that mechanism to obtain common stock. It should be further noted that the insiders of NOHO have never converted any shares in this class and therefore have never owned or sold any common stock. The company has directed counsel to further reduce the authorized shares commensurate to this cancellation. Further updates will be provided as developments occur.

NOHO FILES COMPLAINTS WITH FINRA ALLEGING TRADING ANOMALIES AND COLLUSION
http://ih.advfn.com/p.php?pid=nmona&article=75194608&symbol=DRNK
Phoenix, AZ - July 7, 2017 - InvestorsHub NewsWire - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company"), announced the following:

NOHO, Inc. has filed two complaints with FINRA alleging trading anomalies by market makers and brokerage firms following an internal analysis by the company.

The first complaint focuses on evidence of Regulation SHO violations by market makers employing collusive efforts to manipulate the share price. Rule 203(b)(1), which lies at the core of Regulation SHO and has been in force since Regulation SHO was first adopted in 2004 and became fully effective in January 2005, states:

"A broker or dealer may not accept a short sale order in an equity security from another person, or effect a short sale in an equity security for its own account, unless the broker or dealer has: (i) Borrowed the security, or entered into a bona fide arrangement to borrow the security; or (ii) Reasonable grounds to believe that the security can be borrowed so that it can be delivered on the date delivery is due; and (iii) Documented compliance with this paragraph (b)(1)."

We believe a few market makers have violated the fair market making requirements, Regulation SHO, and Rule 5100 by selling stock short without locating the stock for delivery at settlement and have not been engaged in bona fide market making which lead to conversion or misuse of customer funds, misuse of customer securities, as well as failure to maintain possession or control of fully paid securities without the customer's knowledge.

The second complaint alleges abuse of convertible note holders who misuse Rule 144 by intentionally revising previously executed promissory notes to include a convertible feature and declaring that tacking under Rule 144 applies.

David Mersky, NOHO, Inc.'s CEO, stated, "Upon internal analysis of recent trading activity in our stock, there is solid evidence that certain parties have colluded to depress our share price in violation of Regulation SHO and Rule 5100. The time has come to shed light on these illicit activities and we look forward to working with regulators in this effort."
Additionally, in conjunction with the alleged illegal trading activities stated above, the company has identified certain parties who have made libelous public statements about NOHO's business operations and management. It is alleged that these individuals are "paid bashers" who are employed by market makers and others to disseminate knowingly false information to erode confidence in the company and depress the share price. "We have identified individuals who have continually made and repeated false and defamatory statements about the company and management and have relayed this information to FINRA," Mersky continued. In addition, the company is also pursuing these people outside of the regulatory process and is currently notifying, among others, the state Attorney General's Office in Tennessee, alleging violations of criminal forgery statutes. See, Tennessee Code, Title 39 - Criminal Offenses - 39-14-114.

Sibannac, Inc.
NOHO, Inc.'s CEO, David Mersky, has become the Chief Executive Officer of Sibbanac, Inc. (OTC: SNNC). Mr. Mersky will remain in his role in NOHO and at this time the acquisition by SNNC of IMBUTEK HOLDINGS, CORP., will have no effect on the NOHO shareholders. "While we had originally intended to change the name of NOHO to IMBUTEK to pursue new acquisitions, we have now determined that the NOHO brand is too valuable and must stand alone, in light of recent product distribution and the new FDA registered and clinically tested medicine that is going into production. Sibbanac will change its name to IMBUTEK HOLDINGS CORP, which will allow us to expedite our original plan. Sibbanac is fully reporting and we are catching it up on its filings, which we'll have completed very quickly." The company looks forward to updating NOHO shareholders about the impact of Sibannac's recent developments. For further information, please see the latest 8-K from Sibbanac, Inc.


NOHO LICENSES NEW FDA FORMULATION AND COMPLETES ASSET PURCHASE WITH GREENFIELD FARMS
http://ih.advfn.com/p.php?pid=nmona&artic...ymbol=DRNK
PHOENIX, AZ - June 7, 2017 - InvestorsHub NewsWire - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company" , announced the following:
FDA Formulation
The Company has executed a licensing agreement with DMR Biologics, LLC, of Schofield, Wisconsin, to acquire the exclusive rights to market and sell its homeopathic, FDA registered drug under the NOHO brand. This new, lipid-based gel formulation is taken via a patented, sublingual (under the tongue) delivery method, contained in a small stick pack. The product offers fast and effective relief from Hangover pain and headache in bypassing the digestive system so it can be absorbed much faster than liquid or pill-based formulas. As a homeopathic medicine, it has no contraindicated drug interactions. The product's effectiveness is confirmed by two Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, NOHO has contracted the exclusive rights to the product in the Hangover market. Most Hangover headaches are migranous in nature and there are numerous cross-over symptoms shared between migraine headaches and Hangovers.
David Mersky, NOHO's CEO stated, "Today, we are announcing that the company has acquired the exclusive rights to an FDA registered medicine that will be manufactured as a new NOHO product for the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space as the product is backed by two published clinical studies."
The company is in the process of obtaining a National Drug Code number and has secured financing to begin production of the new formulation within 30 days. Labeling and packaging designs will also be underway so that all approvals will be in place when the product is market ready in approximately 90 days. In addition to the formulation being clinically tested with great success, it is well-suited to both the retail and online markets, as it is small and light (a unit dose is 3ml) and can be easily carried by users or shipped in larger quantities at low cost.
"We are currently in negotiations for a large initial purchase order on the new product, which we hope to close while the initial run is in production. This new relationship will open the doors to the retail market and provide immediate revenue to the company. We'll be disclosing more details as we move ahead, but suffice it to say we're really excited by what's ahead for NOHO," said Mersky.

Greenfield Farms (GRAS)
The company, through Cherry Hill Financial, LLC, has completed the Asset Purchase Agreement with Greenfield Farms Food Inc. (OTC PINK: GRAS). Pursuant to the deal, Cherry Hill's membership interest was acquired in exchange for 49% of GRAS' common stock. As the first of a series of anticipated transactions, the model places NOHO in control of the board of directors of the target.
The agreement requires GRAS to divest itself of its prior operations and bring in a new staff of licensed brokers and support personnel to begin marketing its pre-paid life insurance program to employees of staffing companies throughout the country. Ronald Heineman, GRAS' CEO will remain in place and rely on his years of experience in the staffing industry to access nearly 24,000 employees for enrollments.
The insurance program will pair employee bases with target companies under a co-employment relationship and offer employees life insurance as a 401(k) alternative, providing pre-paid coverage for up to three years.
David Mersky, NOHO, Inc.'s CEO, stated, "We have finally put all the pieces together to complete the acquisition of GRAS so we can begin to put the operations in place to start selling policies. It is a highly specialized and niche insurance offering that requires very particular components. We've got the secret sauce."
GRAS' shares will be booked corporately in NOHO's investment account.

No R/S in 2017 CONFIRMED by Management through e-mail and twitter:
Email excerpt:
We're consolidating our websites. All product sales are now on Amazon as well.
As to your other question, management has announced no reverse split in 2017. Thanks for following up.
Twitter post:
https://twitter.com/NOHOdrink/status/865346088886083584

NOHO Signs Letter of Intent for FDA Registered Drug Formulation
http://www.otcmarkets.com/stock/DRNK/news/NOH...64&b=y
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company" , announced the following:
The Company has signed a letter of intent with DMR Biologic, LLC, of Schonfield, Wisconsin, to acquire the rights to market and sell its homeopathic OTC drug registered with the FDA.
This new formulation is taken via a patented, gel-based delivery method contained in a small stick pack. The product is taken sublingually (under the tongue), offering fast and effective relief from Hangover pain and headache. In bypassing the digestive system, the product is absorbed much faster than liquid or pill-based formulas and has no contraindicated drug interactions. The product's effectiveness is confirmed by multiple Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, under the proposed deal, NOHO would have exclusive rights to the product in the Hangover market and register the new brand with the FDA and obtain a National Drug Code number. The proposed terms also include distribution for a re-branded migraine product which NOHO would market and sell through its new distributor, BNG Enterprises.

David Mersky, NOHO's CEO, stated, "In keeping with our strategy of pursuing undervalued assets like our 2oz Shot and Gold can products when we came into NOHO, we have once again found a great opportunity to bring an FDA compliant product to the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space, as none of the competition has clinically tested data to be able to make specific drug claims." Negotiations also involve NOHO working to re-launch a new iteration of the original migraine drug, called Lipigesic. Mersky continued, "I believe this is a great product that wasn't properly packaged and didn't have the appropriate marketing to support it. The test results are terrific and the migraine market is huge at around 50 million people. We're really good at identifying these hidden gems that require a dust-off and some re-branding. All the time, hard work and cost of the trials and FDA registration is already done."
In addition to the current formulation, the parties are discussing a hemp infused product for NOHO to bring to market. "We have identified a path to infuse Hemp, as a legal food product, into the formula. A Hemp-infused Hangover drug will fly off the shelves through our targeted distribution in smoke shops and vape stores," said NOHO's CEO David Mersky.